

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
IND APPLICATION OF INSULIN DEGLUDEC AND
LIRAGLUTIDE INJECTION, DEVELOPED BY HUISHENG
BIOPHARMACEUTICAL, APPROVED BY NMPA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, the investigational new drug (IND) application of insulin degludec and liraglutide injection, developed by Huisheng Biopharmaceutical Co., Ltd. (“**Huisheng Biopharmaceutical**”), a non-wholly owned subsidiary of the Group, for the treatment of type 2 diabetes has been approved by the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (“**China**”).

Insulin degludec and liraglutide injection is the first marketed compound in the world composed of basic insulin analog and GLP-1 analog. It combines the two-component advantages of insulin degludec and liraglutide, has a significant effect on blood glucose lowering and shows weight loss efficacy at the same time. It is used to treat type 2 diabetes. Insulin degludec and liraglutide injection is injected once a day, reducing the frequency of injections and improving medical adherence in patients. When the dosage of insulin is same or lower, its blood glucose lowering effect is superior to basic insulin treatment alone, meanwhile reducing the risk of hypoglycemia and eliminating the side effects of insulin treatment on weight gain. Insulin degludec and liraglutide injection is recommended in the *China Guideline for Type 2 Diabetes (2020 Edition)*. It belongs to Category B drug under the National Reimbursement Drug List (“**NRDL**”).

China has the largest number of diabetes patients in the world. The number of diabetes patients was about 140 million in 2021, and it is predicted that it will increase to 174.4 million in 2045. As a chronic disease, diabetes needs lifelong medication, so the diabetes market has a huge demand. Insulin degludec and liraglutide injection, currently only marketed by its developer Novo Nordisk in China, was approved for marketing in China in October 2021 and was included in the NRDL in 2022. It is currently in a rapid expansion period in China.

About Huisheng Biopharmaceutical

Huisheng Biopharmaceutical is a biopharmaceutical company under Sihuan Pharmaceutical, a large domestic pharmaceutical and medical aesthetics group, focusing on the areas of diabetes and complications. After nine years of construction and development, Huisheng Biopharmaceutical has become one of the few companies in China that has achieved full product coverage in the field of diabetes and related complications, and integrated the whole industrial chain of R&D, production and sales. The company currently has a world-class R&D team with rich experience in diabetes drug research and development. At present, it has more than 40 products in the research product pipeline of diabetes and complications, covering a full range of second-, third-, and new-generation insulin (covering basic, premixed and quick-acting etc.), innovative drugs with the latest mechanism, such as SGLT-2i, GLP-1a, and other hypoglycemic drugs and complication drugs. Huisheng Biopharmaceutical is committed to providing full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 25 October 2023

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.